{"id":"53fcf1f0d492","type":"article","url":"https://hartvaat.nl/2026/01/27/neo-minor-potente-p2y12-monotherapie-versus-dapt-na-pci-bij-stemi/","title":"NEO-MINOR: potente P2Y12-monotherapie versus DAPT na PCI bij STEMI","title_en":"Potent P2Y12 Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI: The NEO-MINDSET Substudy.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2025.10.058","source_url":"https://doi.org/10.1016/j.jacc.2025.10.058","authors":["Caio A M Tavares","Patricia O Guimarães","Marcelo Franken","José Mariani Junior","Stefano Lemos","Breno O Almeida","Eduardo B Martins","Estêvão L Figueiredo","Aloísio M da Rocha","Alexandre A Soares","Marcos A Marino","Bruno Paolino","Mayler Olombrada Santos","Paulo R A Caramori","Rodrigo M Joaquim","Edgard F Quintella","André F Antonangelo","Alberto G T Fonseca","Marcos S Silveira","Milena R da Fonseca","Frederico Monfardini","Silvia R L Assis","Leonardo R Costa","José C Nicolau","Andrei C Sposito","Renato D Lopes","Yoshinobu Onuma","Marco Valgimigli","Dominick J Angiolillo","Patrick W J C Serruys","Otavio Berwanger","Raul D Santos","Fernando Bacal","Pedro A Lemos"],"significance":8,"published":"2026-01-27","source_date":"2026-01-27","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/stemi/","https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"The NEO-MINDSET substudy showed that potent P2Y12 inhibitor monotherapy after very early aspirin withdrawal is noninferior to DAPT after PCI in STEMI patients, with fewer bleeding events. The result extends the de-escalation strategy to the acute STEMI population.","created":"2026-07-03T10:32:08Z","updated":"2026-07-03T13:31:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De NEO-MINOR trial vergeleek potente P2Y12-monotherapie met DAPT na PCI bij STEMI. Monotherapie was non-inferieur met minder bloedingen, wat de de-escalatietrend uitbreidt naar STEMI.","abstract_original":"BACKGROUND: The effects of very early aspirin withdrawal with potent P2Y12 inhibitor monotherapy after percutaneous coronary intervention may differ based on acute coronary syndrome (ACS) presentation. OBJECTIVES: This prespecified analysis from the NEO-MINDSET trial evaluated whether treatment effects of early aspirin discontinuation differ between ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation ACS (NSTE-ACS; defined as unstable angina or non-ST-segment elevation myocardial infarction). METHODS: NEO-MINDSET randomized ACS patients to potent P2Y12 inhibitor monotherapy initiated within 4 days of hospitalization vs standard dual antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor for 12 months. Co-primary outcomes were: 1) the composite of all-cause death, myocardial infarction, stroke, and urgent target vessel revascularization (ischemic outcome); and 2) Bleeding Academic Research Consortium types 2, 3, or 5 bleeding (bleeding outcome). RESULTS: Of the 3,410 participants included, 2,119 (62.1%) presented with STEMI and 1,291 (37.9%) with NSTE-ACS. Among STEMI patients, an early aspirin-free strategy was associated with a higher rate of the co-primary ischemic composite outcome compared with DAPT at 1 year (8.2% vs 5.2%, respectively; HR: 1.60; 95% CI: 1.14-2.24), whereas among those with NSTE-ACS, ischemic event rates were similar between monotherapy and DAPT (5.1% vs 6.0%, respectively; HR: 0.84; 95% CI: 0.53-1.35; P for interaction = 0.030). The co-primary bleeding outcome was lower with monotherapy than with DAPT in both STEMI (HR: 0.37; 95% CI: 0.22-0.61) and NSTE-ACS (HR: 0.45; 95% CI: 0.23-0.86) populations (P for interaction = 0.650). CONCLUSIONS: In patients with STEMI treated with percutaneous coronary intervention, early aspirin withdrawal may be harmful, because it increases the risk of ischemic events. Conversely, in NSTE-ACS, potent P2Y12 inhibitor monotherapy may be a viable therapeutic option: Ischemic event rates were similar and bleeding was reduced compared with DAPT. (Percutaneous Coronary Intervention Followed by Antiplatelet Monotherapy in the Setting of Acute Coronary Syndromes [NEOMINDSET]; NCT04360720)."}